v3.24.1.u1
Revenue Recognition - Collaboration and License Agreement (Details)
 1 Months Ended 3 Months Ended
Nov. 22, 2020
USD ($)
target
program
obligation
Dec. 31, 2022
USD ($)
Nov. 30, 2020
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Deferred revenue, revenue recognized       $ 23,380,000 $ 24,296,000  
Total revenues       36,598,000 64,782,000  
BMS | Collaboration and License Agreement            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Number of biological targets | target 5          
Number of wholly owned programs | program 2          
Number of oncology targets | program 2          
Upfront fee received   $ 55,000,000.0 $ 55,000,000.0      
Maximum milestone payments to be received $ 971,000,000.0          
Number of remain milestone payment targets | target 2          
Number of performance obligations | obligation 1          
Number of programs under agreement | program 5          
Transaction price $ 55,000,000.0          
Total revenues       1,500,000 $ 28,100,000  
Deferred revenue       5,800,000   $ 7,300,000
Receivable from collaboration       0   $ 0
BMS | Collaboration and License Agreement | Neurology and Immunology Product            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Maximum milestone payments to be received 489,000,000.0          
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones 264,000,000.0          
Milestone payments to be received upon achievement of certain specified commercial milestones $ 225,000,000.0          
BMS | Collaboration and License Agreement | Oncology, Neurology, and Immunology Product            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Deferred revenue, revenue recognized       $ 25,000,000.0